Aurinia pharmaceuticals inc stock
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). AUPH.O - Aurinia Pharmaceuticals Inc News | Reuters BRIEF-Aurinia Pharmaceuticals Initiates Rolling Submission Of A New Drug Application To The U.S. FDA For Voclosporin * AURINIA PHARMACEUTICALS INITIATES ROLLING SUBMISSION OF A NEW DRUG AUPH - Aurinia Pharmaceuticals Inc Summary, Stock Quote ... Jan 01, 2010 · Aurinia Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE Mar 05, 2020 Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, …
Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis & News ...
Aurinia Pharmaceuticals Inc - AUPH - Stock Price Today - Zacks View Aurinia Pharmaceuticals Inc AUPH investment & stock information. Get the latest Aurinia Pharmaceuticals Inc AUPH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Aurinia Pharmaceuticals Inc (AUPH) Stock Message Board ... Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need. AUPH - Stock quote for Aurinia Pharmaceuticals Inc. - MSN ... View the latest AUPH stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of Aurinia Pharmaceuticals Inc.. Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH ...
AUPH Stock Quote of Aurinia Pharmaceuticals Inc
AUP:Toronto Stock Quote - Aurinia Pharmaceuticals Inc ... Stock analysis for Aurinia Pharmaceuticals Inc (AUP:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Mar 04, 2020 · Aurinia Pharmaceuticals Inc stock is higher by 183.87% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives AUPH stock a score of 73 out of a possible 100. That rank is …
Mar 12, 2020 · On Wednesday, shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) marked $14.10 per share versus a previous $15.39 closing price. With having a -8.38% loss, an insight into the fundamental values of Aurinia Pharmaceuticals Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. Is Aurinia Pharmaceuticals Inc (AUPH) Stock a Good ... Mar 04, 2020 · Aurinia Pharmaceuticals Inc stock is higher by 183.87% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives AUPH stock a score of 73 out of a possible 100. That rank is … AUP Stock Price, Forecast & News (Aurinia Pharmaceuticals) Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. Aurinia Pharmaceuticals Inc. | LinkedIn Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious
Aurinia Pharmaceuticals To Release Fourth Quarter And Full Year 2019 Financial Results On March 5, 2020. Biotech stock mailbag: Trump, Aurinia, Immunomedics, Cellceutix. By Adam Feuerstein.
Stock Data :: Aurinia Pharmaceuticals Inc. (AUPH) Aurinia Pharmaceuticals Inc. Nasdaq: AUPH. Price AUPH Aurinia Pharmaceuticals Inc. — Stock Price and ...